frederic_knight schreef op 18 juni 2021 08:50:
For 2 consecutive days Immutep Ltd (ASX: IMM) Stock prices are frozen when the market opens.
Yesterday, Immutep Trading halts Until Monday business hours or until the company announces news about the capital increase, whichever comes first.
When the Immutep shares closed on Wednesday (their latest active session), they were exchanging hands for 62 cents per share.
Let’s take a look at what we know about financing biotechnology companies.
According to Immutep, financing will be an institutional arrangement. However, the company has not yet announced how much money it wants to raise during its activities.
In addition, Immutep has yet to clarify why it is raising capital.
Market watchers will pay attention to the company today as details of the latest placements are likely to be announced before the opening on Monday.
The· Last institutional placement It was completed by Immutep in August 2020. Through that placement, the company raised $ 29.6 million by issuing 123.3 million new shares to institutional investors for 24 cents per share.
Immutep’s previous funding was used to increase the budget for clinical programs.
It was primarily aimed at the continued development of the company’s IMP123, a drug that regulates the immune system. However, some of the money raised went to Immutep’s immunosuppressive agonist, IMP761, which is still in the preclinical stage.